Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Marshall Stoller
Photo of Marshall Stoller
Marshall Stoller

Description

Summary

Cystinuria is an inherited autosomal recessive disorder of the kidney that is the result of an inability to reabsorb cystine from the urine. Supersaturation of cystine in the urine produces crystals that precipitate and form stones in the kidney, which can be a cause of obstruction, infection, and chronic kidney disease. Cystine stones constitute a major health challenge for affected individuals with cystinuria because of the frequent recurrence of painful symptoms and the current absence of effective, patient-accepting treatment. A mainstay of therapy is breaking or preventing the cystine bond on the molecular level such that cystine (which is formed from the joining of two cysteine amino acids and their corresponding sulfur atoms) cannot precipitate in the urine. It is hypothesized that a glucose molecule may be able to do this if introduced into the urine. SGLT-2 inhibitors are a class of drug that are FDA approved to treat diabetes mellitus (DM) and heart failure by inhibiting an enzyme in the kidney that allows for reabsorption of glucose from the urine. This effectively increases the concentration of glucose in the urine. Our hypothesis suggests that administration of this drug to patients with cystine will introduce sufficient glucose into the urine to prevent the formation of cystine stones. To date, there has been no published data on the effectiveness of this therapy for this indication, although the dosage and administration would be identical to that already approved by the FDA for the treatment of DM and heart failure.

Details

This is a single center, proof of concept prospective cohort trial designed to assess the effect of daily oral administration of dapagliflozin on cystine formation in freshly voided urine. Five subjects are planned, each with previously diagnosed cystinuria and without current treatment except with potassium citrate medication. Total duration of subject participation with be up to four weeks. Total duration of the study is expected to be 6 months.

Keywords

Cystinuria 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol Dapagliflozin Study Drug

Eligibility

You can join if…

Open to people ages 18 years and up

  • males and females age 18 or older
  • documented cystinuria on prior 24-hour urine collection and/or stone analysis
  • history of previous cystine kidney stones
  • able and willing to provide consent

You CAN'T join if...

  • prior diagnosis of diabetes mellitus (type I or type II)
  • current SGLT-2 inhibitor administration at the time of screening
  • SGLT-2 inhibitor administration within the last year prior to screening
  • vulnerable populations including incarceration status
  • anticipation of pregnancy during the study duration
  • unable to give informed consent
  • non-English primary language
  • pregnancy, lactation, or child- bearing age without birth control devices
  • serious illness likely to cause death within the next 5 years.

Location

  • University of California, San Francisco
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Marshall Stoller
    My clinical and research efforts continue to be centered around the treatment and understanding the pathogenesis of urinary stone disease. I have recently identified zinc as a critical factor in the early mineralization process.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04818034
Phase
Phase 2
Study Type
Interventional
Last Updated